BMJ Open

Oral diazoxide versus placebo for severe or recurrent neonatal hypoglycaemia: Neonatal Glucose Care Optimisation (NeoGluCO) study – a randomised controlled trial

Don Laing 1, Eamon Walsh,1 Jane M Alsweiler,2,3 Sara M Hanning,4 Michael P Meyer,2,5 Julena Ardern,5 Wayne S Cutfield,1,3 Jenny Rogers,1 Greg D Gamble,1 J Geoffrey Chase,6 Jane E Harding,1 Christopher JD McKinlay 2,5

ABSTRACT

Introduction Infants with severe or recurrent transitional hypoglycaemia continue to have high rates of adverse neurological outcomes and new treatment approaches are needed that target the underlying pathophysiology. Diazoxide is one such treatment that acts on the pancreatic β-cell in a dose-dependent manner to decrease insulin secretion.

Methods and analysis Phase IIB, double-blind, two-arm, parallel, randomised trial of diazoxide versus placebo in neonates ≥35 weeks' gestation for treatment of severe (blood glucose concentration (BGC)<1.2 mmol/L or BGC 1.2 to <2.0 mmol/L despite two doses of buccal dextrose gel and feeding in a single episode) or recurrent (≥3 episodes <2.6 mmol/L in 48 hours) transitional hypoglycaemia. Infants are loaded with diazoxide 5 mg/kg orally and then commenced on a maintenance dose of 1.5 mg/kg every 12 hours, or an equal volume of placebo. The intervention is titrated from the third maintenance dose by protocol to target BGC in the range of 2.6–5.4 mmol/L. The primary outcome is time to resolution of hypoglycaemia, defined as the first point at which the following criteria are met concurrently for ≥24 hours: no intravenous fluids, enteral bolus feeding and normoglycaemia. Groups will be compared for the primary outcome using Cox's proportional hazard regression analysis, expressed as adjusted HR with a 95% CI.

Ethics and dissemination This trial has been approved by the Health and Disability Ethics Committees of New Zealand (19CEN189). Findings will be disseminated in peer-reviewed journals, to clinicians and researchers at local and international conferences and to the public.

Trial registration number ACTRN12620000129987.

INTRODUCTION

At least 30% of all newborn infants are at risk of transitional hypoglycaemia or low blood glucose concentration (BGC) due to being born small, large, preterm or the infant of a woman with diabetes.1,2 They require regular testing of BGC in the first 24–48 hours after birth and approximately 50% develop hypoglycaemia and require further testing and intervention. Optimal management of transitional neonatal hypoglycaemia is important not only because of its impact on breast feeding,3,4 and the use of healthcare resources,5,6 but also because of the potential for hypoglycaemia to cause permanent brain injury. We have shown that infants with asymptomatic hypoglycaemia have a twofold to threefold increased likelihood of later neurocognitive difficulties by 4–5 years of age, especially in executive function and visual-motor integration.7 These functions are critical for learning, and even brief transitional neonatal hypoglycaemia has been associated with a twofold increased likelihood of poor school achievement.8 Moreover, in moderately preterm infants, transitional hypoglycaemia
is the main modifiable risk factor for developmental delay at preschool age.\(^9\)

If oral dextrose gel and additional feeding do not correct hypoglycaemia or if there are recurrent episodes, infants are typically admitted to the neonatal unit for frequent or continuous feeding by gastric tube or intravenous dextrose, to correct BGC to a normal range.\(^2\) These infants often have prolonged neonatal admission, ongoing hypoglycaemia despite the provision of intravenous fluids and can be difficult to establish on enteral feeds due to glucose instability.\(^10\) Even with standard management, infants with severe or recurrent transitional hypoglycaemia continue to have higher rates (approximately fourfold) of adverse neurological outcomes.\(^11\)

An important cause of severe or recurrent transitional hypoglycaemia is dysregulated insulin secretion, especially the inability to suppress insulin secretion at low BGC.\(^10\) \(^12\) \(^13\) If insulin secretion remains inappropriately high during the transition period after birth, hepatic glucose output is inadequate for metabolic requirements, and hypoglycaemia ensues. Increasing delivery of exogenous glucose, either with formula or intravenous dextrose, may stimulate additional insulin secretion and cause ongoing suppression of endogenous glucose production, further delaying normal metabolic transition. Thus, alternative management strategies are needed for infants with severe or recurrent transitional hypoglycaemia that address the underlying pathophysiology and promote metabolic transition.

Diazoxide is one such potential treatment that acts on the pancreatic \(\beta\) cell in a dose-dependent manner to decrease insulin secretion by interacting with the sulfonylurea receptor.\(^14\) Advantages of diazoxide include rapid onset of action, oral formulation and low cost. Diazoxide has been used for many decades as a first-line treatment for certain forms of congenital (genetic) hyperinsulinism with a good efficacy and safety profile, although reversible congestive heart failure has been occasionally reported with prolonged high-dose treatment.\(^15\)

Diazoxide has also been used selectively in babies with transient hyperinsulinism. Hoe et al described 21 hyperinsulinaemic babies without known genetic defects, 20 (95\%) of whom were responsive to diazoxide (5–15 mg/kg/day), when commenced at a median age of 13 days.\(^16\) Additionally, in a randomised trial of 30 small-for-gestational-age (SGA) neonates with transient hyperinsulinism in the first 5 days of age, diazoxide at 6–12 mg/kg/day reduced the median time to achieve hypoglycaemic control (40 vs 72 hours, \(p=0.02\)), the total duration of intravenous fluids (114 vs 164 hours, \(p=0.04\)) and time to achieve full feeds (74 vs 124 hours, \(p=0.02\)).\(^17\) There were no apparent adverse events, although episodes of hyperglycaemia were not reported. Together these data suggest that diazoxide may have a role in the early management of severe neonatal hypoglycaemia to reduce the need for intravenous glucose, shorten neonatal unit admissions and facilitate the earlier introduction of enteral feeds.

We are therefore undertaking the Neonatal Glucose Care Optimisation (NeoGluCO) study to determine if early use of low-dose oral diazoxide is beneficial for the treatment of severe or recurrent transitional neonatal hypoglycaemia. This trial was registered with the Australian New Zealand Clinical Trials Registry on 11 February 2020.

AIM

To determine if early use of diazoxide in late preterm and term neonates with severe or recurrent transitional hypoglycaemia reduces time to resolution of hypoglycaemia, defined as achieving enteral bolus feeding and normal BGC without intravenous fluids.

HYPOTHESIS

Diazoxide therapy will improve glycaemic stability, allowing earlier weaning of intravenous fluids and establishment of enteral feeds.

METHODS AND ANALYSIS

Study design

The NeoGluCO study is a phase IIB, double-blind, two-arm, parallel randomised trial of diazoxide versus placebo for treatment of severe or recurrent transitional hypoglycaemia in late preterm and term neonates.

Participants

Infants are eligible for this study if they are born at \(\geq 35\) weeks’ gestation, are admitted to the neonatal care unit in the first week after birth with recurrent or severe hypoglycaemia, and their parents have provided informed written consent. Severe hypoglycaemia is defined as any BGC \(< 1.2\) mmol/L or BGC \(1.2\) to \(< 2.0\) mmol/L despite two doses of buccal dextrose gel and feeding in a single episode; recurrent hypoglycaemia is defined as \(\geq 3\) episodes (one or more consecutive BGC \(< 2.6\) mmol/L) of hypoglycaemia in 48 hours. Infants must also be receiving ongoing management for hypoglycaemia at the time of randomisation, for example, intravenous dextrose, carbohydrate supplements, continuous or frequent feeding (\(\leq 2\) hourly intervals) or inability to wean off formula due to hypoglycaemia. Eligibility is based on BGC measured by a gas analyser (portable or laboratory) or plasma glucose concentration measured on a laboratory chemical analyser.

Infants are excluded if they have a confirmed major congenital malformation or chromosomal disorder, suspected genetic syndrome associated with hypoglycaemia, gastrointestinal disorder likely to affect feed tolerance, confirmed sepsis (culture of a pathogenic organism from blood, cerebrospinal fluid or urine) or hypoxic-ischaemic encephalopathy; are planned or likely to have neonatal surgery; there is a family history
of congenital hyperinsulinism; are suspected of suffering from an inborn error of metabolism; or are a triplet.

**Recruitment, randomisation and allocation concealment**

Recruitment commenced on 14 May 2020. Infants are being recruited at Middlemore Hospital, Counties Manukau Health, South Auckland and Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand. These hospitals provide all tertiary neonatal services for the wider Auckland region. At both sites, neonatal care focuses on supporting breast feeding, skin-to-skin care, keeping mother and baby together where possible and the use of dextrose buccal gel as the first-line management of neonatal hypoglycaemia. Neonatal medical advice is sought if an infant has severe or recurrent hypoglycaemia (as defined above), at which point the infant may be given artificial feed supplements or admitted to the neonatal care unit for intravenous dextrose, depending on caregiver preference and infant risk factors. BGC screening of at-risk infants is commenced between 1 and 2 hours of age using capillary whole blood and a gas analyser (portable or laboratory).

Infants are recruited after birth by investigators, study personnel and clinical staff. Following written, informed parental consent and once all eligibility criteria are met, infants are allocated via an online randomisation system (Clinical Data Research Hub, Liggins Institute, University of Auckland) to one of two masked interventions, diazoxide or placebo. The allocation ratio is 1:1. The allocation sequence was computer-generated with random permuted blocks of four and six, stratified by centre and SGA status (<10th customised centile). Twins are individually randomised.

The interventions are provided in opaque bottles labelled with a four-digit random number. At randomisation, the web-based system assigns the appropriate bottle number according to the allocation sequence. Only the data manager and trial pharmacists have access to the allocation sequence and know the content of bottles; study personnel, clinical staff and parents are blinded to the allocation.

**Interventions**

The active intervention is prepared by hospital trial pharmacists by adding five 100mg diazoxide capsules to 50mL of Ora Blend sugar-free paediatric compounding solution, giving a concentration of 10mg/mL. Infants are loaded with 5mg/kg (0.5mL/kg) orally or by gastric tube and then commenced on a maintenance dose of 1.5mg/kg (0.15mL/kg) every 12 hours. The intervention is prescribed on hospital medication charts as ‘NeoGluCO study drug’ in mL along with the bottle allocation number and is administered by hospital nurses or midwives. The active intervention is physically and chemically stable for up to 35 days at room temperature (25°C) and when refrigerated (2°C–8°C).

The maintenance dose is at the lower end of the range recommended in the New Zealand Formulary for Children. Although infants with congenital hyperinsulinism usually receive higher maintenance doses of 5–10mg/kg/day, our clinical experience has shown that this dose is often too high for infants with transitional hypoglycaemia and may cause hyperglycaemia, whereas lower doses appear to be similarly efficacious but avoid high BGC. Adverse effects, such as congestive heart failure, are also likely to be rare with low-dose treatment.

A bedside algorithm is used to titrate the study drug according to BGC, commencing immediately before the third maintenance dose (Table 1). Once the primary outcome is reached, one further dose of the study drug

<table>
<thead>
<tr>
<th>Table 1 Intervention bedside algorithm</th>
</tr>
</thead>
<tbody>
<tr>
<td>BGC</td>
</tr>
<tr>
<td>≤2.5mmol/L</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>2.6–5.4mmol/L</td>
</tr>
<tr>
<td>5.5–6.9mmol/L</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>≥7mmol/L</td>
</tr>
</tbody>
</table>

The intervention algorithm commences before the third maintenance dose.

BGC, blood glucose concentration; EBM, expressed breast milk.
is given and then the intervention is discontinued. The intervention may also be stopped before the primary outcome is reached as per the titration protocol. Weekly dose adjustment for weight is made if required, once the infant returns to birth weight.

The control intervention consists of an equal volume of Ora Blend (0.5 mL/kg load, 0.15 mL/kg maintenance), combined with a small amount of corn flour (4 g per 50 mL) to ensure that the placebo is identical in appearance to the diazoxide solution. The glucose load from the corn flour is trivial (0.03 g per maintenance dose) and will not affect BGC. Dosing, administration and discontinuation are as per diazoxide.

**Blinding**

Tetrad testing was used to validate the comparability of the control and active interventions in 42 neonatal staff volunteers (36 women; 27 nurses). Four bottles of study drug, two diazoxide and two placebo, were presented to the staff who were asked to examine the bottles and draw up the study drug into a clear syringe. Staff were then asked to group the bottles into two groups of two based on perceived similarities, after which staff were asked to identify the diazoxide and control pairs, using a forced-choice procedure. Only nine participants (21%) correctly paired the study interventions, corresponding to a Thurstonian effect size (95% CI) for sensory discrimination of 0.00 (0.00 to 0.24).

This outcome indicates sensory equivalence of the interventions (an effect size ≤0.61 represents differences too small to be noticed). Of those who identified the correct pairings, only two (22%) correctly identified the diazoxide pair, which is less than the percentage expected by chance alone of 50%.

**Blood glucose target and monitoring**

The target BGC range for infants in the NeoGluCO study is 2.6–5.4 mmol/L, which represents the 10th and 90th centiles, respectively, over the first week in healthy breastfed infants. Management decisions are based on BGC by gas analyser (portable or laboratory) or plasma glucose concentration by laboratory chemical analyser. Capillary, arterial or venous blood samples are acceptable. Because gas analysers provide plasma-equivalent glucose concentration, whole-blood gas analyser and laboratory plasma measurements are used interchangeably without adjustment and are referred to in this protocol as BGC.

BGC are measured at least every 6 hours (pre-feed if on enteral bolus feeding) until the primary outcome is reached. Once the primary outcome is achieved, BGC measurement frequency is at clinical discretion but is performed at least every 12 hours while the infant is receiving the intervention.

Episodes of hypoglycaemia after randomisation (BGC ≤2.5 mmol/L) are managed according to local practice, which could include buccal dextrose gel, increasing enteral feed volume or frequency and starting or increasing intravenous dextrose fluids. If hypoglycaemia occurs after the intervention titration algorithm has commenced (immediately before the third maintenance dose), the maintenance dose may be increased according to the titration protocol (table 1).

Wherever possible, episodes of elevated blood glucose (5.5–6.9 mmol/L) or hyperglycaemia (≥7 mmol/L) will be avoided. If this occurs before commencing the intervention titration algorithm (immediately before the third maintenance dose) intravenous fluids are weaned by 50% or stopped, or if the infant is receiving formula while establishing breast feeding, the supplementary feed volume is halved or stopped. Once the intervention titration algorithm has commenced, intravenous fluids and supplementary feeds are weaned as soon as possible.

**Co-interventions**

Management of fluids and feeding is as per local practice but with the aim of weaning intravenous fluids and introducing enteral feeds as soon as possible once BGC have stabilised.

Glucagon injections are to be used only in emergencies when intravenous access cannot be obtained and BGC persists at <1.2 mmol/L. Glucagon infusions are not permitted. Glucocorticoids are not permitted for the treatment of hypoglycaemia but may be used if deemed essential for the management of other conditions, for example, adrenal insufficiency.

Where possible, infants enrolled in the trial will have subcutaneous real-time continuous glucose monitoring (CGM) (Guardian Connect System, Enlite 3 sensor, Medtronic) to help identify the need for additional BGC testing (supplement). The CGM is calibrated against BGC by a gas analyser, four times in the first 24 hours, then every 12 hours while in situ. Using Bluetooth transmission to a bedside tablet computer and remote cloud monitoring with text alerts, research staff will use predefined Trend Alarm criteria to inform the bedside nurse that a BGC measurement is indicated, that is, sensor glucose concentration (SGC) is trending out of range (table 2). Clinical management decisions are based solely on BGC. The CGM will remain in place for 24 hours after either discontinuation of the study drug or attainment of the primary outcome, whichever is longer, up to a maximum of 7 days. CGM alert and SGC data are recorded along with all BGC measurements for later agreement analysis.

All other neonatal care will occur according to local practice. Open-label diazoxide may be considered in refractory cases once other management strategies have been maximised and after discussion with the attending neonatologist, site principal investigator and a paediatric endocrinologist. This requires unblinding of treatment allocation, which will generally not occur before 2 weeks of age. If emergency unblinding occurs, the intervention will be revealed only to the senior medical staff caring for the infant. Study personnel collecting outcome data will remain blinded to intervention allocation.
Assessments

Demographic, obstetrical and relevant family medical history is collected at study entry. Neonatal clinical data are obtained from the electronic health record and bedside charts. The study schedule is summarised in Table 3.

Blood is collected at baseline and sent to the hospital laboratories to measure plasma concentrations of insulin, β-hydroxybutyrate, free fatty acids, creatinine and blood gases. All infants will have a standard metabolic screen by Guthrie card at ≥48 hours. Additional heparinised blood is collected before the third study maintenance dose (36 hours after commencing the intervention) and plasma is stored for later measurement of insulin, creatinine and diazoxide concentrations. Fasting tests are not part of the study protocol but may be considered on clinical grounds, for example, if transitional hypoglycaemia is unusually severe or prolonged, or if other diagnoses are suspected.

To assess if low-dose diazoxide has any effect on cardiac function, infants at the primary site (Middlemore Hospital) will undergo a cardiac ultrasound at ≥72 hours after commencing the study intervention to assess (a) ductal patency, flow and shunt; (b) pulmonary arterial pressure; and (c) cardiac function. Infants with suspected congestive heart failure will also undergo formal echocardiography.

Outcomes

The primary outcome is time to resolution of hypoglycaemia, defined as the first time point at which all of the following criteria are met concurrently:

- No intravenous fluids for ≥24 hours (time recorded at the end of the 24-hour period).
- Enteral bolus feeding for ≥24 hours, defined as (a) breast feeding without supplements; or (b) breast feeding with supplements at >2 hourly intervals, or (c) if not breast feeding, gastric tube or bottle feeds at 3–4 hourly intervals (time recorded at the end of the 24-hour period).
- Normoglycaemia for ≥24 hours, defined as a minimum of four pre-feed BGC in the target range of 2.6–5.4 mmol/L spanning >20 hours (last BGC on September 2, 2022 by guest. Protected by copyright.http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2021-059452 on 17 August 2022. Downloaded from http://bmjopen.bmj.com/
measured within 4 hours of primary outcome time point) and no BGC out of range for ≥24 hours (time recorded at the end of the period).

The following secondary outcomes will be assessed from the time of randomisation:

- Time to achieve normoglycaemia (as per primary outcome).
- Time to establish enteral bolus feeding (as per primary outcome).
- Time to establish full sucking feeds defined as ≥5 full breast feeds (≥10 min) in 24 hours or ≥120 mL/kg/day of expressed breast milk or formula by bottle (up to discharge to home).
- Type of feeding at discharge from hospital and to home (breast milk, formula, mixed).
- Use of intravenous fluids and type.
- Duration of intravenous fluids (up to discharge from hospital).
- Episodes of hypoglycaemia (BGC < 2.6 mmol/L), elevated glucose concentration (BGC < 5.5–6.9 mmol/L) and hyperglycaemia (BGC ≥ 7 mmol/L), including frequency, duration, timing and treatment before, during and after the episode (up to discharge from hospital).
- Number of blood glucose tests: during the study intervention and hospital admission.
- Duration of admission to first discharge home: neonatal care, postnatal ward, community birthing unit.
- Duration of study intervention (up to discharge from hospital).
- Guthrie metabolic screen (≥48 hours from birth).
- Plasma insulin, creatinine and diazoxide concentrations at ≥36 hours after commencing the intervention.
- Death (up to discharge from hospital).
- Seizures (total; presumed hypoglycaemic) (up to discharge from hospital).
- Discontinuation of study intervention due to elevated BGC or hyperglycaemia (up to discharge from hospital).
- Discontinuation of study intervention due to another adverse event (serious; non-serious) (up to discharge from hospital).
- Congestive heart failure (respiratory distress as evidenced by tachypnoea, recession or use of oxygen or positive pressure support with consistent chest X-ray findings, including cardiomegaly, plethora, interstitial fluid or effusions) (up to discharge from hospital).
- Commencement of low flow oxygen or positive pressure respiratory support (up to discharge from hospital).
- Cardiac ultrasound (Middlemore Hospital) at (≥72 hours).
  - Ductus arteriosus: closed; trivial (<1.5 mm and a constricted pattern on Doppler); patent (≥1.5 mm, growing, pulsatile or bidirectional pattern on Doppler).
  - Pulmonary hypertension: pulmonary artery pressure ≥systemic as estimated by tricuspid regurgitant jet (right ventricular-atrial gradient +5 mm Hg) or ductal shunt right to left (≥20%) with characteristic pulmonary Doppler envelope (time to peak velocity/right ventricular ejection time < 20%).
  - Cardiac impairment: left ventricular internal diameter diastolic z-score ≥2 and reduced systolic function (fractional shortening < 25% or myocardial performance index > 0.41).

Data management

Web-based data management is provided by the Clinical Data Research Hub at the Liggins Institute, University of Auckland. This includes a bespoke online randomisation system, with intervention stock management, which is integrated with the Research Electronic Data Capture (REDCap) system. Study data are collected directly into electronic case record forms (eCRF). Range and logic checks are used to reduce data entry errors. CGM data are captured in a secure cloud account and subsequently uploaded to the REDCap system.

A data monitor checks all eCRF for completeness and logic errors, after which eCRFs are locked. If the data monitor identifies potential errors, an electronic query is raised and referred to the site for checking.

Statistical analysis

Data analysis will be performed in SAS V.9.4 (SAS Institute). Customised birth weight centiles will be calculated using GROW software (Perinatal Institute, UK). Population z-scores for weight, length and head circumference at birth will be calculated using UK-WHO centiles. Categorical data will be presented as number and per cent, and continuous data as mean and SD or median and IQR, as appropriate. Count data will be presented as median and IQR or grouped into ordinal categories. Denominators will be given for all outcomes.

In the primary analysis, intervention groups will be compared for the primary outcome using Cox’s proportional hazard regression analysis, with treatment effect expressed as adjusted HR with a 95% CI. The analysis will be right censored at 4 weeks. Proportionality assumptions will be assessed by inspecting Kaplan-Meier curves and Schoenfeld residuals. Secondary outcomes will be compared between groups using generalised linear models (normal, binomial or Poisson) with treatment effect presented as adjusted OR, count ratio, mean difference or ratio of geometric means (positively skewed data), as appropriate, with 95% CI. Regression models will be adjusted for stratification variables (centre and customised birth weight centile, fixed effects), gestation length (fixed effect) and non-independence of multiples (random effect). If models fail to converge, the analysis algorithm will be optimised and the maximum number of iterations increased to get convergence with minimum Akaike information criteria. If this is unsuccessful, adjustment variables may be collapsed or excluded if necessary.
for model convergence. For significance tests, the alpha level will be set at 0.05 (two-tailed). No adjustment will be made for multiple comparisons but results for secondary outcomes will be interpreted cautiously. All infants who meet eligibility will be included in the primary analysis (modified intention-to-treat analysis). Secondary exploratory analysis may include per-protocol analysis of the primary outcome.

Sample size
A trial of 74 babies randomised in a 1:1 ratio (37 per group) will give 80% power to detect a relative hazard of 2.0 (two-tailed alpha 0.05), assuming 90% of infants in each group have a primary outcome event within the study period (PASS Software V.16). A HR of 2.0 indicates that the diazoxide group reaches the primary outcome at twice the rate (events per unit of time) of the control group. An adaptive sample size approach will be adopted where the number of randomised participants will be increased by the number of participants who withdraw or who are lost to follow-up.

Data and safety monitoring
An independent Data Monitoring and Safety Committee (DMSC) is monitoring recruitment, completeness of data acquisition and participant safety. The DMSC advises the Trial Steering Committee (TSC) on trial continuation or protocol modification. DMSC Terms of Reference were agreed on before commencement of trial.

The following serious adverse events (SAE) are reported to the DMSC for immediate review:
- Death.
- Seizure.
- Congestive heart failure.
- Discontinuation of study intervention due to another SAE, as judged by the site principal investigator or attending neonatologist (an adverse event is considered serious if it is immediately life-threatening, requires prolongation of hospitalisation or substantial escalation in care or results in persistent or significant disability or incapacity).

SAE are reported until the time of primary hospital discharge. The TSC Chair notifies the DMSC Chair of all SAE within 72 hours of onset. The DMSC reviews SAE within 1 week of receiving the SAE report, to determine if participation in the trial is likely to be a causative factor and reports back to the TSC with the findings.

The DMSC will undertake an interim safety review when the primary outcome is known for 25% and 60% of participants, including rates of SAE and the following adverse events (AE) by masked treatment group:
- Hyperglycaemia (≥7 mmol/L).
- Discontinuation of study intervention due to elevated BGC (5.5–6.9 mmol/L) or hyperglycaemia.
- Discontinuation of study intervention due to another AE (non-serious).
- Commencement of low flow oxygen or positive pressure respiratory support.

There is no planned interim efficacy analysis.

Patient and public involvement
The NeoGluCO study was presented and developed at an ON TRACK Network (https://ontrack.perinatalociety.org.nz/) clinical trials workshop, Auckland, New Zealand, in February 2020, which was attended by consumers, including parents of infants admitted to neonatal intensive care. Consumer input was received about study design and participant information.

ETHICS AND DISSEMINATION
Approval has been obtained from the Central Health and Disability Ethics Committee of New Zealand (reference 19CEN189) and by the local institutional research review committees at each centre.

The primary and secondary outcomes will be published in an international peer-reviewed journal and disseminated via presentations at local and international conferences to researchers and clinicians. The decision to publish is the responsibility of the TSC, which will have full access to the final data set. A lay summary of the research findings will be made available to those parents who indicated a wish to receive these on their consent forms.

Data availability
For each main publication, the corresponding data set will be electronically archived with the Clinical Data Research Hub, Liggins Institute, University of Auckland. Anonymised data may be shared with external researchers on request, according to the Data Sharing Protocol of Research Hub (https://wiki.auckland.ac.nz/display/ontrack/Data+Sharing).

DISCUSSION
Despite current management, infants with severe or recurrent transitional hypoglycaemia continue to have higher rates (approximately fourfold) of adverse neurological outcomes than at-risk infants without hypoglycaemia. In addition, they often have prolonged neonatal admission, ongoing blood glucose instability despite the provision of intravenous fluids and can be difficult to establish on enteral feeds. New treatment approaches are needed that target the underlying pathophysiology, especially dysregulated insulin secretion, such as low-dose diazoxide.

A systematic review found low certainty evidence from one randomised trial that early use of diazoxide in SGA infants receiving intravenous dextrose for transitional neonatal hypoglycaemia decreased the duration of intravenous fluids and time to full enteral feeding by approximately 2 days. Although there are no apparent adverse effects in this trial, several case series have highlighted a range of possible side effects, including pulmonary hypertension, oedema, heart failure, neutropenia, reopening of the ductus arteriosus and necrotising enterocolitis. However, in other reports, serious side effects in otherwise
well infants were rare, suggesting that some of the conditions associated with diazoxide may reflect confounding. Randomised controlled trials are needed to generate unbiased effect estimates.

The NeoGluCO study will provide high-quality evidence to determine if early use of low-dose oral diazoxide for severe or recurrent transitional hypoglycaemia in late preterm and term infants reduces the time to resolution of hypoglycaemia.

Author affiliations
1Liggins Institute, The University of Auckland, Auckland, New Zealand
2Department of Paediatrics: Child and Youth Health, The University of Auckland, Auckland, New Zealand
3Starship Children’s Health, Auckland, New Zealand
4School of Pharmacy, The University of Auckland, Auckland, New Zealand
5Kidz First Neonatal Care, Counties Manukau District Health Board, Auckland, New Zealand
6College of Engineering, University of Canterbury, Christchurch, New Zealand

Acknowledgements Lex Doyle, Rebecca Simmons and members of the ON TRACK Network for assistance in developing and refining the study design. Lisa Mravicich for assistance in setting up the study and study coordination. Safaet Hosain and Rashadul Hasan and the Clinical Data Research Hub, Liggins Institute, the University of Auckland for data management support. Lisa Chen and Michelle Ure for pharmacy support. Data Monitoring and Safety Committee: Stuart Daitz (Chair), Nicola Austin and Rinki Murphy.

Contributors CJD and DL conceived and developed the study design, drafted the original study protocol, approved the final study protocol and drafted and reviewed the article for publication. EW contributed to the study design, approved the final study protocol and drafted and reviewed the article for publication. JMA, SMH, MPM, JA, WSC, JR, JG and JEH contributed to the study design, approved the final version of the study protocol and reviewed the article for publication. DG adapted with the sample size calculation and statistical analysis plan, contributed to the study design, approved the final version of the study protocol and reviewed the article for publication. All authors are part the Trial Steering Committee.

Funding This work is supported by the University of Auckland (Early Career Research Award, CM) and the Health Research Council of New Zealand (20/651).

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement For each main publication, the corresponding data set will be electronically archived with the Clinical Data Research Hub, Liggins Institute, University of Auckland. Anonymised data may be shared with external researchers upon request, according to the Data Sharing Protocol of Research Hub (https://wiki.auckland.ac.nz/display/ontrack/Data+Sharing).

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Don Laing http://orcid.org/0000-0003-4263-5664
Jane M Alsweiler http://orcid.org/0000-0002-0874-6654
Jane E Harding http://orcid.org/0000-0003-2697-1422
Christopher JD McKinlay http://orcid.org/0000-0003-1088-9467

REFERENCES
20 Ennis JM, Christensen RHB. Precision of measurement in tetrad testing. *Food Qual Prefer* 2014;32:98–106.


